Boncresa (denosumab-mobz) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat osteoporosis in women after menopause who are at high risk for fracture. It is also used to increase bone mass in men with osteoporosis who are at high risk for fracture.
Boncresa is a type of osteoporosis treatment called a RANK ligand (RANKL) inhibitor. It blocks a protein called RANKL that helps control cells that break down bone.
By blocking this protein, Boncresa slows bone breakdown and helps increase bone mass and strength.
Boncresa is a biosimilar of Prolia. This means it is made from living cells and is designed to work like the original medicine. The FDA requires biosimilars to have no meaningful differences in safety or how well they work.
Doctors prescribe Boncresa when:
Boncresa is given as an injection under the skin by a healthcare provider.
The recommended dose of Boncresa is 60 milligrams given as an injection under the skin once every six months.
People receiving Boncresa should also receive 1,000 milligrams of calcium each day and at least 400 international units of vitamin D each day.
This information is based on prescribing information, but your healthcare provider may tailor your treatment plan. Always follow their guidance.
In clinical studies of denosumab, the active ingredient in Boncresa, the most common side effects differed depending on why people were taking it.
In women with osteoporosis after menopause, common side effects include:
In men with osteoporosis, common side effects include:
In people with glucocorticoid-induced osteoporosis, common side effects include:
In people with bone loss related to certain prostate or breast cancer treatments, side effects include:
Boncresa can cause serious side effects that may require immediate medical attention. These include:
Get medical help right away if you think you are having a serious reaction.
Amneal Pharmaceuticals, the manufacturer of Boncresa, offers the Amneal PATHways Co-Pay Assistance Card. Eligible people with commercial insurance may pay as little as $0 per treatment.
The program also offers support from Patient Access Specialists, including help understanding benefits, exploring affordability options, and receiving program updates.
To learn more, visit Amneal PATHways Patient Support or call 866-426-6325.
Before you start Boncresa:
Tell your doctor if you have any allergies to denosumab-mobz or any ingredients in Boncresa.
Tell your doctor about all medicines you take, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements.
Also tell your doctor if you:
Take good care of your teeth and gums while receiving Boncresa. Brush and floss regularly, and tell your dentist that you receive Boncresa before having dental work.
Do not take Boncresa if you:
Boncresa is also FDA-approved to increase bone mass in men at high risk for fracture who are receiving androgen deprivation therapy for prostate cancer that has not spread to other parts of the body. It is also approved to increase bone mass in women at high risk for fracture who are receiving adjuvant aromatase inhibitor therapy as part of breast cancer care.
If you miss a dose, get the injection as soon as possible. After that, your next dose should be scheduled six months from the date of your last injection.
Boncresa may cause fetal harm. If you can become pregnant, use effective birth control during treatment and for at least five months after your last dose. Tell your doctor right away if you become pregnant during treatment.
If you are breastfeeding or plan to breastfeed, tell your doctor. It is not known if Boncresa passes into breast milk. Do not breastfeed while receiving Boncresa.
These answers are fact-checked by our editorial staff.
How effective is Boncresa for osteoporosis?
In a three-year study of women with osteoporosis after menopause:
In a separate one-year study of men with osteoporosis:
How long does Boncresa take to work for osteoporosis?
Studies of denosumab found that its effects on bone breakdown began soon after treatment. A marker of bone breakdown called serum type 1 C-telopeptide decreased by about 85 percent within three days. The largest decreases were seen by month 1.
At years 1, 2, and 3, denosumab significantly reduced new spine fractures in women with osteoporosis after menopause. It also increased bone mineral density at the bone sites measured after three years. The studies do not say exactly when a person will notice Boncresa working.
Should I take Boncresa for osteoporosis if I have an infection?
Boncresa may increase the risk of serious infections. These can include infections of the skin, abdomen, urinary tract, or ear.
People who take medicines that weaken the immune system, or who already have a weakened immune system, may have a higher risk of serious infections. Your doctor should consider the benefits and risks of Boncresa before treatment.
If you develop a serious infection while receiving Boncresa, your doctor should decide whether you should continue treatment. Get medical care promptly if you develop signs or symptoms of a serious infection, including cellulitis, which is a serious skin infection.
On MyOsteoTeam, people share their experiences with osteoporosis, get advice, and find support from others who understand.
Learn more about Boncresa and osteoporosis care:
More resources from MyOsteoTeam that mention Boncresa
Become a member to get even more